Company overview
QIAGEN offers OEM and custom manufacturing solutions for life sciences and pharma, including bulk production of enzymes, oligos, buffers, kits, assays, and automation systems. With over 40 years of experience, they provide scalable, high-quality products from prototype to commercial scale through ISO and GMP-certified global facilities. Strategic partnerships enable rapid market entry while ensuring compliance, quality, and consistency.
Sample to Insight - QIAGEN is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, CDMO & Manufacturing partner serving United States & Americas. Core focus areas include qiagen oem, custom manufacturing, pharma suppliers, bulk reagents, gmp certified.
Industry categories: Life Science Reagents, CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.qiagen.com/gb
- Categories
- Life Science Reagents, CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- qiagen oem, custom manufacturing, pharma suppliers, bulk reagents, gmp certified
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What manufacturing capabilities does QIAGEN offer for pharma and life sciences?
- QIAGEN provides customizable bulk manufacturing of enzymes, oligos, buffers, kits, assays, automation, and software integration, scalable from prototype to high-volume production with global facilities.
- What regulatory certifications does QIAGEN hold?
- QIAGEN's manufacturing facilities are ISO and GMP certified, ensuring compliance, quality control, and consistency for biotechnology products.
- What geographies does QIAGEN support for OEM solutions?
- QIAGEN offers worldwide manufacturing capabilities with offices and facilities located globally, providing coordinated production planning and commercial support.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
